Furthermore, semaglutide, like other GLP-1 agonists, has demonstrated a cardioprotective effect, reducing cardiovascular events in people with diabetes
oral= 2.0 mg/kg/day) produced performances that were significantly improved over that seen in the scopolamine groups (p .05)
So few documented side effects mainly reflects absence of rigorous data , not proof of safety
Additionally, peptides should be kept in tightly sealed containers for example vials to protect them from moisture and air exposure, which can compromise their quality
Every reputable protocol is written in IU, and the only conversion that matters is IU-to-insulin-syringe-units, which depends entirely on the reconstitution concentration used (see the table above)